MEAGAN MEFFERT: Open Payments
NPI 1649990722 · CATOOSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 45 payments from 12 companies in 2025. Trend: 2023 $335 · 2024 $1,362 · 2025 $962
Food & beverage: $954Education: $8
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $226 |
| AstraZeneca Pharmaceuticals LP | 8 | $168 |
| Grifols USA, LLC | 4 | $97 |
| ABBVIE INC. | 4 | $87 |
| GlaxoSmithKline, LLC. | 4 | $68 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| Blueprint Medicines Corporation | 2 | $41 |
Products named: DUPIXENT, FASENRA, Xembify, NUCALA, NEFFY, CUVITRU, AIRSUPRA, AYVAKIT.
Industry payments across OK — which companies pay providers there.
